Palbocent is indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer: 🔹 In combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women. 🔹 In combination with fulvestrant in women with disease progression following prior endocrine therapy.

Dosage and administration

Sales Unit: 1 pack containing 21 capsules, each containing 125 mg of Palbociclib. ⚠️ APPLICATION INSTRUCTIONS: Dosage: The standard dose is 125 mg (one capsule) taken orally once daily for 21 consecutive days, followed by 7 days off treatment (a 28-day cycle). Method: Swallow capsules whole. Must be taken with food to ensure optimal absorption and consistent plasma levels. Consistency: Take the dose at approximately the same time each day. Storage: Store in the original package at a temperature below 30°C in a dry place.

⛔ Pregnancy and Breastfeeding: Known to cause fetal harm. Strictly contraindicated during pregnancy and nursing. ⛔ Organ Impairment: Severe hepatic or renal dysfunction. Hypersensitivity to Palbociclib or any of its excipients. Pediatric use (safety and efficacy in children under 18 have not been established).

Professional medical monitoring, including regular blood counts, is required. Potential side effects include: 🩸 Hematologic: Neutropenia (very common), leukopenia, anemia, and thrombocytopenia. 🏃♂️ General: Fatigue (asthenia) and physical weakness. 🤢 Gastrointestinal: Nausea, stomatitis, vomiting, and diarrhea. 🦠 Infections: Increased risk of infections due to low white blood cell counts. 💅 Dermatologic: Alopecia (hair thinning) and skin rash.

Palbocent 125 — Palbociclib 125 mg, 21 pcs, Incepta Pharmaceuticals

100% original product

Active ingredient

Palbociclib

Manufacturer

Incepta Pharmaceuticals

Dosage 125 mg

Dosage form Capsules

Capsules per pack 21

Palbocent 125 Capsules — Palbociclib 125 mg (21 Capsules) Incepta

Name: Palbocent 125
Brand: Incepta Pharmaceuticals
SKU: PROD-254
Price: 7981 UAH
Availability: InStock

7981₴ ~~9311₴~~ -14%

Palbocent 125 mg (Palbociclib) is an advanced targeted anticancer therapy and a first-in-class selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Its mechanism of action focuses on blocking the cell cycle in the G1 phase, thereby preventing the division and growth of malignant cells in hormone-sensitive tumors. Palbocent significantly delays disease progression when administered in conjunction with endocrine therapy.

Manufacturer: Incepta Pharmaceuticals Ltd. This medicinal product is a high-quality generic of the innovator drug Ibrance. It is manufactured under strict quality control standards, ensuring full bioequivalence and identical therapeutic efficacy to the brand-name medication.

Key Features:

✅ Selective Inhibition: Specifically targets CDK4/6 proteins, which are key drivers of cancer cell proliferation.
✅ Endocrine Synergy: Potentiates the efficacy of aromatase inhibitors and fulvestrant.
✅ Clinical Evidence: Proven to significantly extend progression-free survival in patients with metastatic breast cancer.

Palbocent is indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer:

🔹 In combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women.
🔹 In combination with fulvestrant in women with disease progression following prior endocrine therapy.

Sales Unit: 1 pack containing 21 capsules, each containing 125 mg of Palbociclib.

⚠️ APPLICATION INSTRUCTIONS:

Dosage: The standard dose is 125 mg (one capsule) taken orally once daily for 21 consecutive days, followed by 7 days off treatment (a 28-day cycle).
Method: Swallow capsules whole. Must be taken with food to ensure optimal absorption and consistent plasma levels.
Consistency: Take the dose at approximately the same time each day.
Storage: Store in the original package at a temperature below 30°C in a dry place.

⛔ Pregnancy and Breastfeeding: Known to cause fetal harm. Strictly contraindicated during pregnancy and nursing.
⛔ Organ Impairment: Severe hepatic or renal dysfunction.
Hypersensitivity to Palbociclib or any of its excipients.
Pediatric use (safety and efficacy in children under 18 have not been established).

Professional medical monitoring, including regular blood counts, is required. Potential side effects include:

🩸 Hematologic: Neutropenia (very common), leukopenia, anemia, and thrombocytopenia.
🏃‍♂️ General: Fatigue (asthenia) and physical weakness.
🤢 Gastrointestinal: Nausea, stomatitis, vomiting, and diarrhea.
🦠 Infections: Increased risk of infections due to low white blood cell counts.
💅 Dermatologic: Alopecia (hair thinning) and skin rash.

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 11.04.2026